◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › GLENMARK › Revenue

Glenmark Pharmaceuticals Limited (GLENMARK) Revenue 2022–2026

DATA UPDATED 2026-09-20

Glenmark Pharmaceuticals Limited annual revenue for fiscal 2026 was ₹167.1 billion, an increase of 27.1% from ₹131.5 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

GLENMARK Annual Revenue

Revenue (annual)2026-03-312025-03-312024-03-312023-03-312022-03-31
Total Revenue₹167.1B₹131.5B₹116.4B₹114.3B—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GLENMARK Quarterly Revenue

Revenue (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue₹39.3B₹37.6B₹38.9B₹60.0B₹30.6B—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

More GLENMARK metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All GLENMARK financial statements → Interactive GLENMARK charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.